Members Members Residents Job Board
Join Today Renew Your Membership Make A Donation
2006 Abstracts: Effect of Alvimopan on Gastrointestinal (GI) Recovery Following Small Bowel Resection (SBR) in Patients With and Without Crohn’s Disease (CD): Results of a Pooled Analysis of 3 Randomized, Placebo-Controlled Trials
Back to 2006 Program and Abstracts
Effect of Alvimopan on Gastrointestinal (GI) Recovery Following Small Bowel Resection (SBR) in Patients With and Without Crohn’s Disease (CD): Results of a Pooled Analysis of 3 Randomized, Placebo-Controlled Trials
Bruce Wolff1, Eugene Viscusi2, Conor Delaney3, Wei Du4, John G. Fort4, Lee Techner4; 1Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN; 2Department of Anesthesiology, Jefferson Medical College, Philadelphia, PA; 3Division of Colorectal Surgery, University Hospitals of Cleveland, Cleveland, OH; 4Adolor Corporation, Exton, PA

Crohn’s disease is a common indication for bowel resection (BR), and the prevalence of surgery (strictureplasty or BR) in this setting ranges from 38% to 96%. Postoperative ileus (POI), a temporary impairment of GI function, occurs after abdominal surgery. Alvimopan, a novel, peripherally acting, mu-opioid receptor antagonist under investigation for the management of POI, accelerated GI recovery in patients undergoing laparotomy for BR or total abdominal hysterectomy in 3 multicenter phase III trials. Pooled data from these trials were analyzed for patients with and without CD who received SBR. Trials enrolled patients ≥18 years old who were scheduled for postoperative opioid IV patient-controlled analgesia. Alvimopan (6 or 12 mg) or placebo was administered 0.5 to 5 hours before surgery and twice daily starting postoperative day (POD) 1 until hospital discharge for ≤ 7 PODs. Cox proportional hazard ratios were used to analyze treatment effects on time to events and to provide an estimate (in hours) of treatment effect. The primary endpoint was GI-3 recovery (time to first flatus or bowel movement [BM] and toleration of solid food). Secondary endpoints included time to first BM and time to hospital discharge order written. Of the patients who participated in the phase III alvimopan trials, 47 patients with CD and 54 patients without CD underwent SBR. Results are reported in Table 1. Although the number of patients in this analysis was small, patients who received alvimopan (regardless of their CD diagnosis) had reduced time to GI recovery and discharge compared with placebo. Moreover, efficacy was comparable for patients with and without CD.
Table 1. Time to Recovery in Patients Undergoing SBR With and Without CD, MITT Population

 

Patients With CD

Patients Without CD

 

Placebo n = 11

Alvimopan 6 mg n = 19

Alvimopan 12 mg n = 17

Placebo n = 17

Alvimopan 6 mg n = 20

Alvimopan 12 mg n = 17

GI-3 HR (CI) Time to event, median hours

- 115

1.37(0.6,3.1) 100

2.88(1.2,6.8) 71

- 98

2.33(1.2,4.7) 73

2.79(1.3,6.0) 69

BM HR (CI) Time to event, median hours

- 88

1.35(0.6,3.0) 77

1.84(0.8,4.2) 69

- 89

3.19(1.5,6.9) 51

3.12(1.4,7.0) 51

DCO written HR (CI) Time to event, median hours

- 134

1.49(0.7,3.4) 108

2.43(1.1,5.6) 91

- 118

1.97(1.0,3.9) 96

2.62(1.2,5.5) 89


SBR = Small bowel resection; CD = Crohn’s disease; MITT = Modified intent to treat; GI-3 = Time to first flatus or BM and toleration of solid food; HR = Hazard ratio; CI = Confidence interval; BM = Bowel movement; DCO = Discharge order.


Back to 2006 Program and Abstracts


Society for Surgery of the Alimentary Tract

Facebook Twitter YouTube

Email SSAT Email SSAT
500 Cummings Center, Suite 4400, Beverly, MA 01915 500 Cummings Center
Suite 4400
Beverly, MA 01915
+1 978-927-8330 +1 978-927-8330
+1 978-524-0498 +1 978-524-0498
Links
About
Membership
Publications
Newsletters
Annual Meeting
Join SSAT
Job Board
Make a Pledge
Event Calendar
Awards